Scandinavian journal of rheumatology
-
Scand. J. Rheumatol. · Mar 2009
Randomized Controlled Trial Multicenter Study Comparative StudyA randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.
To compare the adverse event (AE)-related discontinuation rate with celecoxib vs. diclofenac when given to reduce joint pain associated with knee or hip osteoarthritis (OA) in elderly patients. ⋯ Treatment with celecoxib 200 mg once daily and diclofenac 50 mg twice daily resulted in similar rates of AE-related study discontinuation in elderly patients with OA. Celecoxib and diclofenac demonstrated comparable efficacy in relieving the signs and symptoms of OA. However, the proportion of patients with cardiorenal and hepatic AEs was significantly lower in the celecoxib group than the diclofenac group.
-
Scand. J. Rheumatol. · Jan 2009
Comparative StudyThe extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI).
To assess the extent and pattern of irreversible organ damage in patients with Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), polyarteritis nodosa (PAN), and Churg-Strauss syndrome (CSS) by a cross-sectional point prevalence study within a defined geographical area. ⋯ Damage remains an important problem for patients with systemic vasculitis despite effective remission-inducing drugs. Only a small fraction of patients are unmarked by their disease.
-
Scand. J. Rheumatol. · Jan 2009
Comparative StudyAssociation of hypoxia-inducible factor 1A (HIF1A) gene polymorphisms with systemic sclerosis in a French European Caucasian population.
Systemic sclerosis (SSc) is a connective tissue disease characterized by generalized microangiopathy leading to chronic hypoxia. The aim of this study was to determine whether polymorphisms of the hypoxia-inducible factor 1A gene (HIF1A) affects susceptibility to SSc in a large French European Caucasian population. ⋯ We observed an association between the HIF1A gene and SSc in a European Caucasian population, supporting a role for HIF1 in the pathophysiology of SSc.
-
Scand. J. Rheumatol. · Jan 2009
Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
To describe, in a 7-year follow-up study, the use of infliximab in patients with refractory posterior uveitis and scleritis. ⋯ Infliximab could be an effective and safe treatment in patients with posterior uveitis and scleritis refractory to conventional therapy.